Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report) was the target of a large decrease in short interest during the month of August. As of August 31st, there was short interest totaling 9,742 shares, a decrease of 55.2% from the August 15th total of 21,732 shares. Based on an average daily trading volume, of 41,401 shares, the short-interest ratio is currently 0.2 days.
Ono Pharmaceutical Stock Performance
Shares of OPHLY stock opened at $5.00 on Monday. The firm has a 50 day moving average price of $5.01 and a two-hundred day moving average price of $5.00. Ono Pharmaceutical has a 12-month low of $3.71 and a 12-month high of $5.75.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
Featured Stories
- Five stocks we like better than Ono Pharmaceutical
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
